Effectiveness and impact of rotavirus vaccines in Europe, 2006-2014

Vaccine

Volumn 33, Issue 18, 2015, Pages 2097-2107

  Karafillakis, Emilie ^a   Hassounah, Sondus ^a   Atchison, Christina ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Children; Diarrhoea; Gastroenteritis; Rotavirus; Vaccines

Indexed keywords

ROTAVIRUS VACCINE; LIVE VACCINE; RIX4414 VACCINE;

DATA BASE; DIARRHEA; DRUG EFFICACY; EUROPE; GASTROENTERITIS; HEALTH CARE UTILIZATION; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PUBLIC HEALTH; PUBLICATION; REVIEW; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW; UNITED STATES; VACCINATION; CHILD; HOSPITALIZATION; IMMUNOLOGY; LEGISLATION AND JURISPRUDENCE; MALE; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; ROTAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; TIME;

CHILD; CHILD, PRESCHOOL; EUROPE; GASTROENTERITIS; HOSPITALIZATION; HUMANS; LATIN AMERICA; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TIME FACTORS; UNITED STATES; VACCINATION; VACCINES, ATTENUATED;

EID: 84926408279     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.016     Document Type: Review

References (39)

1. Centre for Disease Control and Prevention, Rotavirus surveillance-worldwide, 2009. Morb Mortal Wkly Rep 2011; 60(16): 514-516.
2. Soriano-Gabarro M., Mrukowicz J., Vesikari T., Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006, 25(1 Suppl.):S7-S11.
3. Vesikari T., Karvonen A., Prymula R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370(9601):1757-1763.
4. Vesikari T., Karvonen A., Ferrante S.A., Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr 2010, 169(11):1379-1386.
5. World Health Organisation, Rotavirus vaccines. WHO Position Paper-January 2013. Wkly Epidemiol Rec 2013; 88(5):49-64.
6. Parez N., Giaquinto C., Du Roure C., et al. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect Dis 2014, 14(5):416-425. 10.1016/S473-3099(14)70035-0.
7. World Health Organisation. Regional Office for Europe, Countries in the WHO European Region [Online]. Available at (accessed 5 August 2014). http://www.who.int/about/regions/euro/en/.
8. Paulke-Korinek M., Kollaritsch H., Aberle S.W., et al. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria. Vaccine 2013, 31(24):2686-2691.
9. Braeckman T., Van Herck K., Meyer N., et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ 2012, 345:e4752.
10. Vesikari T., Uhari M., Renko M., et al. Impact and effectiveness of RotaTeq vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland. Pediatr Infect Dis J 2013, 32(12):1365-1373.
11. Adlhoch C., Hoehne M., Littmann M., et al. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany: 2010-2011. Pediatr Infect Dis J 2013, 32(2):e82-e89.
12. Muhsen K., Shulman L., Kasem E., et al. Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case-control study. Hum Vaccin 2010, 6(6):450-454.
13. Muhsen K., Chodick G., Goren S., Shalev V., Cohen D. The uptake of rotavirus vaccine and its effectiveness in preventing acute gastroenteritis in the community. Vaccine 2010, 29(1):91-94.
14. Bellido-Blasco J.B., Sabater-Vidal S., Salvador-Ribera MdM, et al. Rotavirus vaccination effectiveness: a case-case study in the EDICS project, Castellon (Spain). Vaccine 2012, 30(52):7536-7540.
15. Castilla J., Beristain X., Martinez-Artola V., et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre: Spain. Vaccine 2012, 30(3):539-543.
16. Martinon-Torres F., Bouzon Alejandro M., Redondo Collazo L., et al. Effectiveness of rotavirus vaccination in Spain. Hum Vaccin 2011, 7(7):757-761.
17. Paulke-Korinek M., Rendi-Wagner P., Kundi M., Kronik R., Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 2010, 29(4):319-323.
18. Paulke-Korinek M., Kundi M., Rendi-Wagner P., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011, 29(15):2791-2796.
19. Zlamy M., Kofler S., Orth D., et al. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis 2013, 13:112.
20. Zeller M., Rahman M., Heylen E., et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010, 28(47):7507-7513.
21. Braeckman T., Van Herck K., Raes M., Vergison A., Sabbe M., Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011, 30(1 Suppl.):S21-S24. 10.1097/INF.0b013e3181fefc51.
22. Raes M., Strens D., Vergison A., Verghote M., Standaert B. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 2011, 30(7):e120-e125. 10.1097/INF.0b013e318214b811.
23. Hanquet G., Ducoffre G., Vergison A., et al. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine 2011, 29(29-30):4698-4703. (Epub May 13). 10.1016/j.vaccine.2011.04.098.
24. Leino T., Ollgren J., Salo H., Tiihonen P., Kilpi T. First year experience of rotavirus immunisation programme in Finland. Vaccine 2012, 31(1):176-182.
25. Hemming M., Rasanen S., Huhti L., Paloniemi M., Salminen M., Vesikari T. Major reduction of rotavirus: but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr 2013, 172(6):739-746.
26. Gagneur A., Nowak E., Lemaitre T., et al. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study. Vaccine 2011, 29(21):3753-3759. (Epub Apr 13). 10.1016/j.vaccine.2011.03.035.
27. Dudareva-Vizule S., Koch J., An der Heiden M., Oberle D., Keller-Stanislawski B., Wichmann O. Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. Hum Vaccin Immunother 2012, 8(10):1407-1415. (Epub 2012 Sep 7). 10.4161/hv.21593.
28. Gil-Prieto R., Gonzalez-Escalada A., Alvaro-Meca A., et al. Impact of non-routine rotavirus vaccination on hospitalizations for diarrhoea and rotavirus infections in Spain. Vaccine 2013, 31(43):5000-5004. (Epub Jul 30). 10.1016/j.vaccine.2013.05.109.
29. Martinon-Torres F., Martinon-Torres N., Bouzon Alejandro M., et al. Acute gastroenteritis hospitalizations among children aged <5 years before and after introduction of rotavirus vaccines: a hospital-based surveillance study in Galicia, Spain. Hum Vaccin Immunother 2012, 8(7):946-952. (Epub 2012 Jun 8). 10.4161/hv.20178.
30. Bouzon Alejandro M., Diez Domingo J., Martinon-Torres F. Circovirus and impact of temporary withdrawal of rotavirus vaccines in Spain. Hum Vaccin 2011, 7(7):798-799. (Epub 2011 Jul 1). 10.4161/hv.7.7.15683.
31. Martinon-Torres F., Aramburo A., Martinon-Torres N., et al. A reverse evidence of rotavirus vaccines impact. Hum Vaccin Immunother 2013, 9(6):1289-1291. (Epub 2013 Mar 6). 10.4161/hv.24182.
32. Giaquinto C., Dominiak-Felden G., Van Damme P., et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin 2011, 7(7):734-748.
33. Rha B., Tate J.E., Payne D.C., et al. Effectiveness and impact of rotavirus vaccines in the United States-2006-2012. Expert Rev Vaccines 2014, 13(3):365-376. (Epub 2014 Jan 6). 10.1586/14760584.2014.877846.
34. Vesikari T., Itzler R., Karvonen A., et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009, 28(2):345-351.
35. Correia J.B., Patel M.M., Nakagomi O., et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010, 201(3):363-369. 10.1086/649843.
36. Jit M., Mangen M.J., Melliez H., Yazdanpanah Y., Bilcke J., Salo H., et al. An update to the cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2010, 28(47):7457-7459. (Epub Sep 21). 10.1016/j.vaccine.2010.08.060.
37. Jit M., Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007, 25(20):3971-3979. (Epub 2007 Mar 13).
38. Soares-Weiser K., Maclehose H., Bergman H., Ben-Aharon I., Nagpal S., Goldberg E., et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2012, 11:CD008521. 10.1002/14651858.CD008521.pub3.
39. Rha B., Tate J.E., Weintraub E., et al. Intussusception following rotavirus vaccination: an updated review of the available evidence. Expert Rev Vaccines 2014, 26:1-10.